VEGFR2/CD309 anticorps (pTyr951)

N° du produit ABIN7139090

Cet anticorps Lapin Polyclonal détecte spécifiquement VEGFR2/CD309 dans WB, IHC, ELISA et IF. Il présente une réactivité envers Humain.

Aperçu rapide pour VEGFR2/CD309 anticorps (pTyr951) (ABIN7139090)

Antigène: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp VEGFR2/CD309 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (IHC), ELISA, Immunofluorescence (IF)

Détail du produit anti-VEGFR2/CD309 anticorps

Épitope: pTyr951

Réactivité croisée: Humain, Souris, Rat

Purification: Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi

Immunogène: Peptide sequence around phosphorylation site of tyrosine 951 (K-D-Y(p)-V-G) derived from Human VEGFR2.

Isotype: IgG

Information d'application

Indications d'application: WB:1:500-1:1000, IHC:1:50-1:100, IF:1:100-1:200,

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Supplied at 1.0 mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C,-80 °C

Stockage commentaire: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Détails sur VEGFR2/CD309

Antigène: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Autre désignation: KDR

Sujet:

Background: Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions

Zeng H, et al. (2001) J Biol Chem. 276(35): 32714-32719.
Dougher M, et al. (1999) Oncogene. 18(8): 1619-1627.

Aliases: CD309 antibody, CD309 antigen antibody, EC 2.7.10.1 antibody, Fetal liver kinase 1 antibody, FLK-1 antibody, FLK1 antibody, FLK1, mouse, homolog of antibody, Kdr antibody, Kinase insert domain receptor (a type III receptor tyrosine kinase) antibody, Kinase insert domain receptor antibody, KRD1 antibody, Ly73 antibody, Protein tyrosine kinase receptor FLK1 antibody, Protein-tyrosine kinase receptor flk-1 antibody, soluble VEGFR2 antibody, Tyrosine kinase growth factor receptor antibody, Vascular endothelial growth factor receptor 2 antibody, VEGFR 2 antibody, VEGFR antibody, VEGFR-2 antibody, VEGFR2 antibody, VGFR2_HUMAN antibody

UniProt: P35968

Pathways: Signalisation RTK, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling